Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53
- PMID: 11528400
- DOI: 10.1038/ng714
Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53
Abstract
The p53 protein can inhibit cell cycling or induce apoptosis, and is thus a critical regulator of tumorigenesis. This protein is negatively regulated by a physical interaction with MDM2, an E3 ubiquitin ligase. This interaction is critical for cell viability; loss of Mdm2 causes cell death in vitro and in vivo in a p53-dependent manner. The recently discovered MDM2-related protein MDM4 (also known as MDMX) has some of the same properties as MDM2. MDM4 binds and inhibits p53 transcriptional activity in vitro. Unlike MDM2, however, MDM4 does not cause nuclear export or degradation of p53 (refs. 9,10). To study MDM4 function in vivo, we deleted Mdm4 in mice. Mdm4-null mice died at 7.5-8.5 dpc, owing to loss of cell proliferation and not induction of apoptosis. To assess the importance of p53 in the death of Mdm4-/- embryos, we crossed in the Trp53-null allele. The loss of Trp53 completely rescued the Mdm4-/- embryonic lethality. Thus, MDM2 and MDM4 are nonoverlapping critical regulators of p53 in vivo. These data define a new pathway of p53 regulation and raise the possibility that increased MDM4 levels and the resulting inactivation of p53 contribute to the development of human tumors.
Similar articles
-
Mutation at p53 serine 389 does not rescue the embryonic lethality in mdm2 or mdm4 null mice.Oncogene. 2004 Oct 7;23(46):7644-50. doi: 10.1038/sj.onc.1207793. Oncogene. 2004. PMID: 15361844
-
Tissue-specific differences of p53 inhibition by Mdm2 and Mdm4.Mol Cell Biol. 2006 Jan;26(1):192-8. doi: 10.1128/MCB.26.1.192-198.2006. Mol Cell Biol. 2006. PMID: 16354690 Free PMC article.
-
Switching mechanisms of cell death in mdm2- and mdm4-null mice by deletion of p53 downstream targets.Cancer Res. 2003 Dec 15;63(24):8664-9. Cancer Res. 2003. PMID: 14695178
-
Mouse models of Mdm2 and Mdm4 and their clinical implications.Chin J Cancer. 2013 Jul;32(7):371-5. doi: 10.5732/cjc.012.10286. Epub 2013 Jan 18. Chin J Cancer. 2013. PMID: 23327795 Free PMC article. Review.
-
Regulation of kidney development by the Mdm2/Mdm4-p53 axis.J Mol Cell Biol. 2017 Feb 1;9(1):26-33. doi: 10.1093/jmcb/mjx005. J Mol Cell Biol. 2017. PMID: 28096292 Free PMC article. Review.
Cited by
-
MDM2 oligomers: antagonizers of the guardian of the genome.Oncogene. 2016 Dec 1;35(48):6157-6165. doi: 10.1038/onc.2016.88. Epub 2016 Apr 4. Oncogene. 2016. PMID: 27041565 Free PMC article. Review.
-
The associations between MDM4 gene polymorphisms and cancer risk.Oncotarget. 2016 Aug 23;7(34):55611-55623. doi: 10.18632/oncotarget.10877. Oncotarget. 2016. PMID: 27742919 Free PMC article.
-
MDM2 is an important prognostic and predictive factor for platin-pemetrexed therapy in malignant pleural mesotheliomas and deregulation of P14/ARF (encoded by CDKN2A) seems to contribute to an MDM2-driven inactivation of P53.Br J Cancer. 2015 Mar 3;112(5):883-90. doi: 10.1038/bjc.2015.27. Epub 2015 Feb 10. Br J Cancer. 2015. PMID: 25668009 Free PMC article.
-
MDMX (MDM4), a Promising Target for p53 Reactivation Therapy and Beyond.Cold Spring Harb Perspect Med. 2016 Jul 1;6(7):a026237. doi: 10.1101/cshperspect.a026237. Cold Spring Harb Perspect Med. 2016. PMID: 27371671 Free PMC article. Review.
-
ATM and Chk2-dependent phosphorylation of MDMX contribute to p53 activation after DNA damage.EMBO J. 2005 Oct 5;24(19):3411-22. doi: 10.1038/sj.emboj.7600812. Epub 2005 Sep 15. EMBO J. 2005. PMID: 16163388 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Molecular Biology Databases
Research Materials
Miscellaneous